371 related articles for article (PubMed ID: 28060449)
1. Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Ohta Y; Darwish M; Hishikawa N; Yamashita T; Sato K; Takemoto M; Abe K
Geriatr Gerontol Int; 2017 Nov; 17(11):1843-1848. PubMed ID: 28060449
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for Alzheimer's disease.
Birks J
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
4. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 46(3):687-93. PubMed ID: 26402513
[TBL] [Abstract][Full Text] [Related]
6. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
7. Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
Fukui Y; Hishikawa N; Ichinose J; Sato K; Nakano Y; Morihara R; Ohta Y; Yamashita T; Abe K
Geriatr Gerontol Int; 2017 Nov; 17(11):1991-1999. PubMed ID: 28276131
[TBL] [Abstract][Full Text] [Related]
8. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
9. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
10. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
11. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Wattmo C; Wallin AK; Minthon L
BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
[TBL] [Abstract][Full Text] [Related]
14. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction.
Hishikawa N; Fukui Y; Sato K; Ohta Y; Yamashita T; Abe K
Geriatr Gerontol Int; 2017 Oct; 17(10):1384-1391. PubMed ID: 27578455
[TBL] [Abstract][Full Text] [Related]
16. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease.
Tokuchi R; Hishikawa N; Matsuzono K; Takao Y; Wakutani Y; Sato K; Kono S; Ohta Y; Deguchi K; Yamashita T; Abe K
Geriatr Gerontol Int; 2016 Apr; 16(4):440-5. PubMed ID: 25952367
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
20. Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).
Matsuzono K; Sato K; Kono S; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 48(3):757-63. PubMed ID: 26402119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
